In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study
Abstract The Comparative Activity of Carbapenems Testing (COMPACT) Study was designed to determine the in vitro potency of doripenem compared with imipenem and meropenem against a large number of contemporary Gram-negative pathogens from more than 100 centres across Europe and the Asia-Pacific regio...
Gespeichert in:
| Veröffentlicht in: | International journal of antimicrobial agents 2010-12, Vol.36 (6), p.501-506 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 506 |
|---|---|
| container_issue | 6 |
| container_start_page | 501 |
| container_title | International journal of antimicrobial agents |
| container_volume | 36 |
| creator | Christiansen, K.J Ip, M Ker, H.B Mendoza, M Hsu, L Kiratisin, P Chongthaleong, A Redjeki, I.S Quintana, A Flamm, R Garcia, J Cassettari, M Cooper, D Okolo, P Morrissey, I |
| description | Abstract The Comparative Activity of Carbapenems Testing (COMPACT) Study was designed to determine the in vitro potency of doripenem compared with imipenem and meropenem against a large number of contemporary Gram-negative pathogens from more than 100 centres across Europe and the Asia-Pacific region and to assess the reliability of Etest methodology for doripenem minimum inhibitory concentration (MIC) determination against these pathogens. Data from eight countries within the Asia-Pacific region, which collected 1612 bacterial isolates, are presented here. Etest methodology was found to be a reliable method for MIC determination. Doripenem showed in vitro activity similar to or better than meropenem and at least four-fold better than imipenem against Enterobacteriaceae. Against Pseudomonas aeruginosa , doripenem was also the most active of the three carbapenems in vitro. However, in vitro results do not necessarily correlate with clinical outcome. |
| doi_str_mv | 10.1016/j.ijantimicag.2010.08.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_00640449v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0924857910003493</els_id><sourcerecordid>787042693</sourcerecordid><originalsourceid>FETCH-LOGICAL-c546t-16b5933e19c44d498c4c7bd804b658978ac229beac620d3099e40b09e2957f003</originalsourceid><addsrcrecordid>eNqNkstuEzEUhkcIREPhFZBZIMRiwrHHczELpCiCtlJQK7WsLY_nTOIwYwfbiZRn5KXwkFIuK1bH-vWd6-8se0VhToFW77Zzs1U2mtFotZ4zSDo0cwD2KJvRpmZ5LWjxOJuBYDxvylqcZc9C2ALQsuDl0-yMQVMJRtks-35lycFE74jS0aTXkbiedM6bHVocibIdcXGDnmjlW_VTDEStlbEhEu1sxHHnvPJHcuHVmFtcq1QHyU7FjVujDcQEN6iIHem9G8nGhZ2JajAhKQkyaGNiLElNyCIYld8obXqjice1cfZ9imE_JCbNNTHL6883i-Xd3-xt3HfH59mTXg0BX9zH8-zLp493y8t8dX1xtVyscl3yKua0aktRFEiF5rzjotFc123XAG-rshF1ozRjokWlKwZdAUIghxYEMlHWPUBxnr091d2oQe68GdP20ikjLxcrOWkAFQfOxYEm9s2J3Xn3bY8hytEEjcOgLLp9kHVTA2dVmuc8EydSexeCx_6hNAU52S638g_b5WS7hCY1Yyn35X2XfTti95D5y-cEvL4HVNBq6L2y2oTfXMELJpppteWJw3S_g0Evg04OaeyMRx1l58x_jfPhnyp6MDZhw1c8Yti6vbfJIEllYBLk7fRPp29KIV2Xp1v8AIgN6Ow</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>787042693</pqid></control><display><type>article</type><title>In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Christiansen, K.J ; Ip, M ; Ker, H.B ; Mendoza, M ; Hsu, L ; Kiratisin, P ; Chongthaleong, A ; Redjeki, I.S ; Quintana, A ; Flamm, R ; Garcia, J ; Cassettari, M ; Cooper, D ; Okolo, P ; Morrissey, I</creator><creatorcontrib>Christiansen, K.J ; Ip, M ; Ker, H.B ; Mendoza, M ; Hsu, L ; Kiratisin, P ; Chongthaleong, A ; Redjeki, I.S ; Quintana, A ; Flamm, R ; Garcia, J ; Cassettari, M ; Cooper, D ; Okolo, P ; Morrissey, I</creatorcontrib><description>Abstract The Comparative Activity of Carbapenems Testing (COMPACT) Study was designed to determine the in vitro potency of doripenem compared with imipenem and meropenem against a large number of contemporary Gram-negative pathogens from more than 100 centres across Europe and the Asia-Pacific region and to assess the reliability of Etest methodology for doripenem minimum inhibitory concentration (MIC) determination against these pathogens. Data from eight countries within the Asia-Pacific region, which collected 1612 bacterial isolates, are presented here. Etest methodology was found to be a reliable method for MIC determination. Doripenem showed in vitro activity similar to or better than meropenem and at least four-fold better than imipenem against Enterobacteriaceae. Against Pseudomonas aeruginosa , doripenem was also the most active of the three carbapenems in vitro. However, in vitro results do not necessarily correlate with clinical outcome.</description><identifier>ISSN: 0924-8579</identifier><identifier>EISSN: 1872-7913</identifier><identifier>DOI: 10.1016/j.ijantimicag.2010.08.002</identifier><identifier>PMID: 20869212</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Anti-Bacterial Agents - pharmacology ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Asia ; Biological and medical sciences ; Carbapenem ; Carbapenems - pharmacology ; Doripenem ; Enterobacteriaceae ; Gram-negative ; Gram-Negative Bacteria - drug effects ; Gram-Negative Bacteria - isolation & purification ; Gram-Negative Bacterial Infections - microbiology ; Humans ; Imipenem - pharmacology ; Infectious Disease ; Medical sciences ; Microbial Sensitivity Tests ; Pacific Islands ; Pharmacology. Drug treatments ; Pseudomonas ; Surveillance ; Thienamycins - pharmacology</subject><ispartof>International journal of antimicrobial agents, 2010-12, Vol.36 (6), p.501-506</ispartof><rights>Elsevier B.V. and the International Society of Chemotherapy</rights><rights>2010 Elsevier B.V. and the International Society of Chemotherapy</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c546t-16b5933e19c44d498c4c7bd804b658978ac229beac620d3099e40b09e2957f003</citedby><cites>FETCH-LOGICAL-c546t-16b5933e19c44d498c4c7bd804b658978ac229beac620d3099e40b09e2957f003</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijantimicag.2010.08.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23432980$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20869212$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-00640449$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Christiansen, K.J</creatorcontrib><creatorcontrib>Ip, M</creatorcontrib><creatorcontrib>Ker, H.B</creatorcontrib><creatorcontrib>Mendoza, M</creatorcontrib><creatorcontrib>Hsu, L</creatorcontrib><creatorcontrib>Kiratisin, P</creatorcontrib><creatorcontrib>Chongthaleong, A</creatorcontrib><creatorcontrib>Redjeki, I.S</creatorcontrib><creatorcontrib>Quintana, A</creatorcontrib><creatorcontrib>Flamm, R</creatorcontrib><creatorcontrib>Garcia, J</creatorcontrib><creatorcontrib>Cassettari, M</creatorcontrib><creatorcontrib>Cooper, D</creatorcontrib><creatorcontrib>Okolo, P</creatorcontrib><creatorcontrib>Morrissey, I</creatorcontrib><title>In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study</title><title>International journal of antimicrobial agents</title><addtitle>Int J Antimicrob Agents</addtitle><description>Abstract The Comparative Activity of Carbapenems Testing (COMPACT) Study was designed to determine the in vitro potency of doripenem compared with imipenem and meropenem against a large number of contemporary Gram-negative pathogens from more than 100 centres across Europe and the Asia-Pacific region and to assess the reliability of Etest methodology for doripenem minimum inhibitory concentration (MIC) determination against these pathogens. Data from eight countries within the Asia-Pacific region, which collected 1612 bacterial isolates, are presented here. Etest methodology was found to be a reliable method for MIC determination. Doripenem showed in vitro activity similar to or better than meropenem and at least four-fold better than imipenem against Enterobacteriaceae. Against Pseudomonas aeruginosa , doripenem was also the most active of the three carbapenems in vitro. However, in vitro results do not necessarily correlate with clinical outcome.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Asia</subject><subject>Biological and medical sciences</subject><subject>Carbapenem</subject><subject>Carbapenems - pharmacology</subject><subject>Doripenem</subject><subject>Enterobacteriaceae</subject><subject>Gram-negative</subject><subject>Gram-Negative Bacteria - drug effects</subject><subject>Gram-Negative Bacteria - isolation & purification</subject><subject>Gram-Negative Bacterial Infections - microbiology</subject><subject>Humans</subject><subject>Imipenem - pharmacology</subject><subject>Infectious Disease</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Pacific Islands</subject><subject>Pharmacology. Drug treatments</subject><subject>Pseudomonas</subject><subject>Surveillance</subject><subject>Thienamycins - pharmacology</subject><issn>0924-8579</issn><issn>1872-7913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkstuEzEUhkcIREPhFZBZIMRiwrHHczELpCiCtlJQK7WsLY_nTOIwYwfbiZRn5KXwkFIuK1bH-vWd6-8se0VhToFW77Zzs1U2mtFotZ4zSDo0cwD2KJvRpmZ5LWjxOJuBYDxvylqcZc9C2ALQsuDl0-yMQVMJRtks-35lycFE74jS0aTXkbiedM6bHVocibIdcXGDnmjlW_VTDEStlbEhEu1sxHHnvPJHcuHVmFtcq1QHyU7FjVujDcQEN6iIHem9G8nGhZ2JajAhKQkyaGNiLElNyCIYld8obXqjice1cfZ9imE_JCbNNTHL6883i-Xd3-xt3HfH59mTXg0BX9zH8-zLp493y8t8dX1xtVyscl3yKua0aktRFEiF5rzjotFc123XAG-rshF1ozRjokWlKwZdAUIghxYEMlHWPUBxnr091d2oQe68GdP20ikjLxcrOWkAFQfOxYEm9s2J3Xn3bY8hytEEjcOgLLp9kHVTA2dVmuc8EydSexeCx_6hNAU52S638g_b5WS7hCY1Yyn35X2XfTti95D5y-cEvL4HVNBq6L2y2oTfXMELJpppteWJw3S_g0Evg04OaeyMRx1l58x_jfPhnyp6MDZhw1c8Yti6vbfJIEllYBLk7fRPp29KIV2Xp1v8AIgN6Ow</recordid><startdate>20101201</startdate><enddate>20101201</enddate><creator>Christiansen, K.J</creator><creator>Ip, M</creator><creator>Ker, H.B</creator><creator>Mendoza, M</creator><creator>Hsu, L</creator><creator>Kiratisin, P</creator><creator>Chongthaleong, A</creator><creator>Redjeki, I.S</creator><creator>Quintana, A</creator><creator>Flamm, R</creator><creator>Garcia, J</creator><creator>Cassettari, M</creator><creator>Cooper, D</creator><creator>Okolo, P</creator><creator>Morrissey, I</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope></search><sort><creationdate>20101201</creationdate><title>In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study</title><author>Christiansen, K.J ; Ip, M ; Ker, H.B ; Mendoza, M ; Hsu, L ; Kiratisin, P ; Chongthaleong, A ; Redjeki, I.S ; Quintana, A ; Flamm, R ; Garcia, J ; Cassettari, M ; Cooper, D ; Okolo, P ; Morrissey, I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c546t-16b5933e19c44d498c4c7bd804b658978ac229beac620d3099e40b09e2957f003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Asia</topic><topic>Biological and medical sciences</topic><topic>Carbapenem</topic><topic>Carbapenems - pharmacology</topic><topic>Doripenem</topic><topic>Enterobacteriaceae</topic><topic>Gram-negative</topic><topic>Gram-Negative Bacteria - drug effects</topic><topic>Gram-Negative Bacteria - isolation & purification</topic><topic>Gram-Negative Bacterial Infections - microbiology</topic><topic>Humans</topic><topic>Imipenem - pharmacology</topic><topic>Infectious Disease</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Pacific Islands</topic><topic>Pharmacology. Drug treatments</topic><topic>Pseudomonas</topic><topic>Surveillance</topic><topic>Thienamycins - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Christiansen, K.J</creatorcontrib><creatorcontrib>Ip, M</creatorcontrib><creatorcontrib>Ker, H.B</creatorcontrib><creatorcontrib>Mendoza, M</creatorcontrib><creatorcontrib>Hsu, L</creatorcontrib><creatorcontrib>Kiratisin, P</creatorcontrib><creatorcontrib>Chongthaleong, A</creatorcontrib><creatorcontrib>Redjeki, I.S</creatorcontrib><creatorcontrib>Quintana, A</creatorcontrib><creatorcontrib>Flamm, R</creatorcontrib><creatorcontrib>Garcia, J</creatorcontrib><creatorcontrib>Cassettari, M</creatorcontrib><creatorcontrib>Cooper, D</creatorcontrib><creatorcontrib>Okolo, P</creatorcontrib><creatorcontrib>Morrissey, I</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>International journal of antimicrobial agents</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Christiansen, K.J</au><au>Ip, M</au><au>Ker, H.B</au><au>Mendoza, M</au><au>Hsu, L</au><au>Kiratisin, P</au><au>Chongthaleong, A</au><au>Redjeki, I.S</au><au>Quintana, A</au><au>Flamm, R</au><au>Garcia, J</au><au>Cassettari, M</au><au>Cooper, D</au><au>Okolo, P</au><au>Morrissey, I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study</atitle><jtitle>International journal of antimicrobial agents</jtitle><addtitle>Int J Antimicrob Agents</addtitle><date>2010-12-01</date><risdate>2010</risdate><volume>36</volume><issue>6</issue><spage>501</spage><epage>506</epage><pages>501-506</pages><issn>0924-8579</issn><eissn>1872-7913</eissn><abstract>Abstract The Comparative Activity of Carbapenems Testing (COMPACT) Study was designed to determine the in vitro potency of doripenem compared with imipenem and meropenem against a large number of contemporary Gram-negative pathogens from more than 100 centres across Europe and the Asia-Pacific region and to assess the reliability of Etest methodology for doripenem minimum inhibitory concentration (MIC) determination against these pathogens. Data from eight countries within the Asia-Pacific region, which collected 1612 bacterial isolates, are presented here. Etest methodology was found to be a reliable method for MIC determination. Doripenem showed in vitro activity similar to or better than meropenem and at least four-fold better than imipenem against Enterobacteriaceae. Against Pseudomonas aeruginosa , doripenem was also the most active of the three carbapenems in vitro. However, in vitro results do not necessarily correlate with clinical outcome.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>20869212</pmid><doi>10.1016/j.ijantimicag.2010.08.002</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0924-8579 |
| ispartof | International journal of antimicrobial agents, 2010-12, Vol.36 (6), p.501-506 |
| issn | 0924-8579 1872-7913 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_00640449v1 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Anti-Bacterial Agents - pharmacology Antibiotics. Antiinfectious agents. Antiparasitic agents Asia Biological and medical sciences Carbapenem Carbapenems - pharmacology Doripenem Enterobacteriaceae Gram-negative Gram-Negative Bacteria - drug effects Gram-Negative Bacteria - isolation & purification Gram-Negative Bacterial Infections - microbiology Humans Imipenem - pharmacology Infectious Disease Medical sciences Microbial Sensitivity Tests Pacific Islands Pharmacology. Drug treatments Pseudomonas Surveillance Thienamycins - pharmacology |
| title | In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T17%3A42%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20activity%20of%20doripenem%20and%20other%20carbapenems%20against%20contemporary%20Gram-negative%20pathogens%20isolated%20from%20hospitalised%20patients%20in%20the%20Asia-Pacific%20region:%20results%20of%20the%20COMPACT%20Asia-Pacific%20Study&rft.jtitle=International%20journal%20of%20antimicrobial%20agents&rft.au=Christiansen,%20K.J&rft.date=2010-12-01&rft.volume=36&rft.issue=6&rft.spage=501&rft.epage=506&rft.pages=501-506&rft.issn=0924-8579&rft.eissn=1872-7913&rft_id=info:doi/10.1016/j.ijantimicag.2010.08.002&rft_dat=%3Cproquest_hal_p%3E787042693%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=787042693&rft_id=info:pmid/20869212&rft_els_id=S0924857910003493&rfr_iscdi=true |